Annual Cash & Cash Equivalents
$8.98 M
-$4.11 M-31.41%
December 1, 2023
Summary
- As of February 8, 2025, XBIO annual cash & cash equivalents is $8.98 million, with the most recent change of -$4.11 million (-31.41%) on December 1, 2023.
- During the last 3 years, XBIO annual cash & cash equivalents has fallen by -$2.54 million (-22.07%).
- XBIO annual cash & cash equivalents is now -50.76% below its all-time high of $18.24 million, reached on December 31, 2021.
Performance
XBIO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$6.84 M
-$459.00 K-6.29%
September 1, 2024
Summary
- As of February 8, 2025, XBIO quarterly cash and cash equivalents is $6.84 million, with the most recent change of -$459.00 thousand (-6.29%) on September 1, 2024.
- Over the past year, XBIO quarterly cash and cash equivalents has dropped by -$984.10 thousand (-12.58%).
- XBIO quarterly cash and cash equivalents is now -65.29% below its all-time high of $19.70 million, reached on September 30, 2021.
Performance
XBIO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
XBIO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.4% | -12.6% |
| 3 y3 years | -22.1% | -36.2% |
| 5 y5 years | +1471.5% | -36.2% |
XBIO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -50.8% | at low | -62.5% | at low |
| 5 y | 5-year | -50.8% | at low | -65.3% | at low |
| alltime | all time | -50.8% | >+9999.0% | -65.3% | >+9999.0% |
Xenetic Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.84 M(-6.3%) |
| Jun 2024 | - | $7.30 M(-6.7%) |
| Mar 2024 | - | $7.82 M(-12.9%) |
| Dec 2023 | $8.98 M(-31.4%) | $8.98 M(-8.1%) |
| Sep 2023 | - | $9.78 M(-8.9%) |
| Jun 2023 | - | $10.73 M(-10.6%) |
| Mar 2023 | - | $11.99 M(-8.4%) |
| Dec 2022 | $13.10 M(-28.2%) | $13.10 M(-5.4%) |
| Sep 2022 | - | $13.85 M(-7.2%) |
| Jun 2022 | - | $14.93 M(-7.6%) |
| Mar 2022 | - | $16.16 M(-11.4%) |
| Dec 2021 | $18.24 M(+58.3%) | $18.24 M(-7.4%) |
| Sep 2021 | - | $19.70 M(+112.3%) |
| Jun 2021 | - | $9.28 M(-7.3%) |
| Mar 2021 | - | $10.01 M(-13.2%) |
| Dec 2020 | $11.53 M(+11.2%) | $11.53 M(+63.4%) |
| Sep 2020 | - | $7.05 M(-12.5%) |
| Jun 2020 | - | $8.07 M(-13.9%) |
| Mar 2020 | - | $9.37 M(-9.7%) |
| Dec 2019 | $10.37 M(+1713.8%) | $10.37 M(-13.9%) |
| Sep 2019 | - | $12.04 M(+1064.6%) |
| Jun 2019 | - | $1.03 M(-48.8%) |
| Mar 2019 | - | $2.02 M(+253.1%) |
| Dec 2018 | $571.60 K(-89.7%) | $571.60 K(-64.6%) |
| Sep 2018 | - | $1.61 M(-50.5%) |
| Jun 2018 | - | $3.26 M(-15.7%) |
| Mar 2018 | - | $3.87 M(-30.1%) |
| Dec 2017 | $5.53 M | $5.53 M(+696.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $694.80 K(-70.2%) |
| Jun 2017 | - | $2.33 M(-46.1%) |
| Mar 2017 | - | $4.32 M(+6.8%) |
| Dec 2016 | $4.05 M(+2962.1%) | $4.05 M(+1810.4%) |
| Sep 2016 | - | $211.90 K(-12.0%) |
| Jun 2016 | - | $240.80 K(-85.0%) |
| Mar 2016 | - | $1.61 M(+1114.5%) |
| Dec 2015 | $132.20 K(-94.7%) | $132.20 K(-89.4%) |
| Sep 2015 | - | $1.25 M(+313.3%) |
| Jun 2015 | - | $301.50 K(-67.8%) |
| Mar 2015 | - | $936.60 K(-62.6%) |
| Dec 2014 | $2.51 M(-48.2%) | $2.51 M(-48.1%) |
| Sep 2014 | - | $4.83 M(-36.5%) |
| Jun 2014 | - | $7.61 M(-29.9%) |
| Mar 2014 | - | $10.86 M(>+9900.0%) |
| Dec 2013 | $4.84 M(+8996.8%) | - |
| Nov 2013 | - | $40.10 K(-24.6%) |
| Aug 2013 | - | $53.20 K(-14.5%) |
| Aug 2013 | $53.20 K(-99.5%) | - |
| May 2013 | - | $62.20 K(+38.2%) |
| Feb 2013 | - | $45.00 K(+40.6%) |
| Dec 2012 | $11.14 M(>+9900.0%) | - |
| Nov 2012 | - | $32.00 K(0.0%) |
| Aug 2012 | - | $32.00 K(-3.3%) |
| Aug 2012 | $32.00 K(+220.0%) | - |
| May 2012 | - | $33.10 K(+190.4%) |
| Feb 2012 | - | $11.40 K |
| Aug 2011 | $10.00 K | - |
FAQ
- What is Xenetic Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Xenetic Biosciences?
- What is Xenetic Biosciences annual cash & cash equivalents year-on-year change?
- What is Xenetic Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Xenetic Biosciences?
- What is Xenetic Biosciences quarterly cash and cash equivalents year-on-year change?
What is Xenetic Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of XBIO is $8.98 M
What is the all time high annual cash & cash equivalents for Xenetic Biosciences?
Xenetic Biosciences all-time high annual cash & cash equivalents is $18.24 M
What is Xenetic Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, XBIO annual cash & cash equivalents has changed by -$4.11 M (-31.41%)
What is Xenetic Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of XBIO is $6.84 M
What is the all time high quarterly cash and cash equivalents for Xenetic Biosciences?
Xenetic Biosciences all-time high quarterly cash and cash equivalents is $19.70 M
What is Xenetic Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, XBIO quarterly cash and cash equivalents has changed by -$984.10 K (-12.58%)